Stock Events

Stock Events

Captor Therapeutics. 

€18.48
0
-€0.26-1.39% Thursday 19:56

Statistics

Day High
18.6
Day Low
18.38
52W High
20.6
52W Low
6.96
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Earnings

1JanExpected
Q4 0
999
333
-333
-999
Expected EPS
N/A
Actual EPS
N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow 60Q.STU. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Vertex Pharmaceuticals
VRTX
Mkt Cap109.45B
Vertex Pharmaceuticals focuses on developing treatments for cystic fibrosis and other diseases, competing in the biotech sector with novel therapies like Captor Therapeutics.
Gilead Sciences
GILD
Mkt Cap161.85B
Gilead Sciences is a biopharmaceutical company that develops drugs for infectious diseases, liver diseases, and cancer, overlapping with Captor Therapeutics' focus on disease-related targets.
Regeneron Pharmaceuticals
REGN
Mkt Cap79.46B
Regeneron Pharmaceuticals is known for its innovation in biopharmaceuticals, directly competing with Captor Therapeutics in the development of therapies for various diseases.
AMGEN
AMGN
Mkt Cap185.74B
Amgen develops innovative human therapeutics, similar to Captor Therapeutics, with a focus on oncology, cardiovascular disease, and other serious illnesses.
Biogen
BIIB
Mkt Cap27.06B
Biogen focuses on neurology, autoimmune disorders, and rare diseases, competing in the biotech space by targeting complex diseases, similar to Captor Therapeutics.
Incyte
INCY
Mkt Cap18.84B
Incyte Corporation works on small molecule drugs for oncology and inflammation, competing in the same therapeutic areas as Captor Therapeutics.
Exelixis
EXEL
Mkt Cap11.42B
Exelixis is involved in the discovery, development, and commercialization of new medicines with a focus on cancer, similar to Captor Therapeutics' therapeutic areas.
Alnylam Pharmaceuticals
ALNY
Mkt Cap40.77B
Alnylam Pharmaceuticals develops RNAi therapeutics, a novel approach that could compete with Captor Therapeutics' focus on innovative drug development.

About

Captor Therapeutics Spolka Akcyjna, a biopharmaceutical company, focuses on the discovery and development of protein degradation drugs for cancer and autoimmune diseases. The company provides Targeted Protein Degradation technology that overcomes many existing drug limitations by removing proteins resistant to available therapeutics. It has five projects at the preclinical stage. The company was incorporated in 2015 and is based in Wroclaw, Poland.
Show more...
CEO
Dr. Thomas Shepherd Ph.D.
Employees
98
Country
Poland
ISIN
PLCPTRT00014

Listings

STU
DE
60Q.STU
MU
DE
60Q.MU
WA
PL
CTX.WA
F
DE
60Q.F

0 Comments

Share your thoughts

FAQ

What is Captor Therapeutics. stock price today?▼
The current price of 60Q.STU is €18.48 EUR — it has decreased by -1.39% in the past 24 hours. Watch Captor Therapeutics. stock price performance more closely on the chart.
What is Captor Therapeutics. stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Captor Therapeutics. stocks are traded under the ticker 60Q.STU.
Is Captor Therapeutics. stock price growing?▼
60Q.STU stock has fallen by -1.6% compared to the previous week, the month change is a -1.7% fall, over the last year Captor Therapeutics. has showed a +155.96% increase.
How many employees does Captor Therapeutics. have?▼
As of May 02, 2026, the company has 98 employees.
In which sector is Captor Therapeutics. located?▼
Captor Therapeutics. operates in the Health & Wellness sector.
When did Captor Therapeutics. complete a stock split?▼
Captor Therapeutics. has not had any recent stock splits.
Where is Captor Therapeutics. headquartered?▼
Captor Therapeutics. is headquartered in Wroclaw, Poland.